SCHEMBL7000574

SCHEMBL7000574

O=S1(=O)c2ccccc2/C(=N/O)CN1CCCN1CCN(c2ccc(F)cc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 9/20 0.53
HTR1A P08908 9/20 0.53
HTR2A P28223 7/20 0.53
HTR7 P34969 5/20 0.53
HTR6 P50406 5/20 0.53
DRD4 P21917 4/20 0.53
DRD3 P35462 4/20 0.53
HTR2C P28335 2/20 0.53
HRH1 P35367 2/20 0.53
ADRA2A P08913 1/20 0.53
ADRA2B P18089 1/20 0.53
ADRA2C P18825 1/20 0.53
SLC6A4 P31645 1/20 0.53
ADRA1A P35348 1/20 0.53
ADRA1B P35368 1/20 0.53
OPRK1 P41145 1/20 0.53
HTR5A P47898 1/20 0.53
SLC6A3 Q01959 1/20 0.53
KCNH2 Q12809 1/20 0.53
TMEM97 Q5BJF2 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7000579 1.00 DRD2 (0.53) DRD2HTR1AHTR2AHTR7HTR6
SCHEMBL7000691 0.92 DRD2 (0.57) DRD2HTR1AHTR2AHTR7HTR6
SCHEMBL7000688 0.92 DRD2 (0.57) DRD2HTR1AHTR2AHTR7HTR6
SCHEMBL6991546 0.86 DRD2 (0.54) DRD2HTR1AHTR2AHTR7HTR6
SCHEMBL7109614 0.84 HTR7 (0.52) DRD2HTR1AHTR2AHTR7HTR6
SCHEMBL7109613 0.84 HTR7 (0.52) DRD2HTR1AHTR2AHTR7HTR6
SCHEMBL5851430 0.82 DRD2 (0.47) DRD2HTR1AHTR2AHTR7HTR6
SCHEMBL5851434 0.82 DRD2 (0.47) DRD2HTR1AHTR2AHTR7HTR6
SCHEMBL6991294 0.82 HTR2A (0.53) HTR2AHTR7HTR6HTR2CKDM4E
SCHEMBL6991299 0.82 HTR2A (0.53) HTR2AHTR7HTR6HTR2CKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6664251-B2 Serotonin receptor antagonist; treating cardiovascular disorder DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2003-12-16 US disclosed
EP-0686632-B1 BENZOTHIAZINE DERIVATIVE DAIICHI SUNTORY PHARMA CO LTD (JP) 2003-08-06 EP disclosed
US-20030078256-A1 Benzothiazine derivative SUNTORY LIMITED (JP) 2003-04-24 US disclosed
US-6316442-B1 TREATMENT OF HEART DISEASE AND CEREBROVASCULAR DISTURBANCES SUNTORY LIMITED (JP) 2001-11-13 US disclosed
US-6001827-A Benzothiazine derivative SUNTORY LIMITED (JP) 1999-12-14 US disclosed
EP-0686632-A1 BENZOTHIAZINE DERIVATIVE SUNTORY LIMITED (JP) 1995-12-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078256-A1 Benzothiazine derivative TPH2, ADRB2, TPH1 DRD2 402/4885HTR1A 7/4885HTR2A 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.